Stem Cell Field is Emerging
Analogous to monoclonal antibody enabling technologies in ‘80s and ‘90s which now have a therapeutic market value in excess of US$44.6b;
Commercial stem cell products are entering the market:
- Prochymal (GvHD) – Osiris (USA)
- Cartistem (Osteoarthritis) – Medipost/Dong-A (Korea);
Most stem cell companies attractively priced based on forward estimates;
Multiple products in Phase 2 and 3
- Sector news flow
- Creates opportunities for Cynata;
Big pharma partnering/M&A:
- Teva/Mesoblast
- Pfizer/Athersys
- United Therapeutics/Pluristem
- Novartis/Regenerex.
To view Presentation please download PDF below:
